The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jawdat, D. M.
Right arrow Articles by Marshall, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jawdat, D. M.
Right arrow Articles by Marshall, J. S.
The Journal of Immunology, 2006, 177: 1755-1762.
Copyright © 2006 by The American Association of Immunologists

Mast Cells Have a Pivotal Role in TNF-Independent Lymph Node Hypertrophy and the Mobilization of Langerhans Cells in Response to Bacterial Peptidoglycan1

Dunia M. Jawdat, Geoffrey Rowden and Jean S. Marshall2

Dalhousie Inflammation Group, Department of Pathology and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Peptidoglycan (PGN) from Gram-positive bacteria, activates multiple immune effector cells. PGN-induced lymph node (LN) hypertrophy and dendritic cell mobilization in vivo were investigated following PGN injection into the skin. Both LN activation and the migration of Langerhans cells (LCs) to draining LNs were dependent on the presence of mast cells as demonstrated using mast cell deficient W/Wv mice. However, these responses did not require TLR2, TLR4, or MYD88. TNF-deficient mice exhibited normal increases in LN cellularity but significantly reduced LC migration. In contrast, responses to IgE-mediated mast cell activation were highly TNF dependent. Complement component C3-deficient mice showed decreased LN hypertrophy and abrogated LC migration in response to PGN. These data demonstrate a critical role for mast cells and complement in LN responses to PGN and illustrate a novel TNF-independent mechanism whereby mast cells participate in the initiation of immunity.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Peptidoglycan (PGN)3 is a potent activator of the innate immune system (reviewed in Ref. 1), which stimulates the production of inflammatory cytokines by multiple cell types (reviewed in Ref. 2). Immune responses to PGN can be mediated through interaction with specific pattern recognition molecules, including TLR2 (3, 4, 5), nucleotide-binding oligomerization domain (NOD)1 (6, 7), NOD2 (8, 9), and peptidoglycan recognition proteins (10). In addition, PGN administered in vivo can activate the three major complement pathways (11, 12, 13). Despite the importance of this molecule in initiating early immune responses, the critical cells and receptor systems involved in PGN-induced lymph node (LN) activation and dendritic cell (DC) mobilization in vivo have not previously been investigated.

Mast cells have been widely studied in allergy, however, they also have a critical role as sentinel cells in host defense (14, 15). Mast cells express a wide range of immune receptors that aid in pathogen recognition, including TLRs, complement receptors, and CD48 (reviewed in Ref. 16). Mast cells are strategically located at host-environment interfaces, such as the skin. They produce a wide range of mediators including histamine, arachidonic acid derivatives, and numerous cytokines and chemokines, which can be selectively released (17, 18). In addition, mast cells are a source of TNF. Mast cells are thus far the only cell type described to have presynthesized TNF, which can be released within minutes of mast cell activation. In addition, they have the capability to newly synthesize and secrete this pivotal cytokine (19, 20). Mast cells have been widely implicated in aspects of host defense such as neutrophil recruitment following Gram-negative bacterial challenge, leading to bacteria clearance (14, 15), T cell activation (21), and LN hypertrophy (22). TNF has been shown to be the major mast cell-derived factor responsible for these processes. However, the role of mast cells in responses to Gram-positive bacteria is less well studied and may involve alternate mechanisms. Murine mast cells have previously been shown to respond to PGN predominantly via a TLR2-dependent mechanism to facilitate neutrophil recruitment. There is also evidence for local mast cell degranulation in the skin following administration of PGN (23).

The innate and adaptive immune responses are closely related and interdependent. Although the role of mast cells in innate immunity is well established, their role in adaptive immunity is not well understood (24). Key processes in the initiation of adaptive immune responses are the mobilization and migration of tissue activated DCs into the draining LN and the activation of the local LN. Together these provide an optimal environment for circulating lymphocytes to come in contact with DCs to initiate an immune response. Langerhans cells (LCs) are a specialized subset of immature DCs found in the epidermis of the skin. They can be identified by their expression of CD207 or "Langerin." The expression of this marker is lost once they have migrated into the draining LN (25). We have previously shown that the migration of LCs, a type of immature DCs, from the skin into the draining auricular LN in response to a classical IgE-mediated allergic immune stimulus is mast cell dependent (26). We have also shown that histamine, via H2 receptors, is a major mediator in this process.

In the current study, we examined the mechanism of LN hypertrophy and LC migration in response to Staphylococcus aureus-derived PGN. Our results demonstrate critical roles for both mast cells and complement activation but not TLR2, TLR4, or MyD88 and demonstrate a novel TNF-independent pathway for mast cell-mediated LN hypertrophy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

C57BL/6 mice, genetically mast cell-deficient WBB6F1-W/Wv (W/Wv) matched with congenic WBB6F1-+/+ (+/+) mice, TLR4-deficient C57BL/10ScNJ matched with C57BL/10J, complement component 3 (C3)-deficient B6129S4-C3 matched with C57BL/6 mice, TNF-deficient B6;129S6-TNF mice matched with B6129SF2 mice (The Jackson Laboratory) and TLR2-deficient mice on a C57BL/6 background (a gift from Dr. S. Akira, Osaka, Japan), MyD88-deficient mice and matched C57BL/6 controls were used. All mice were 6–10 wk of age and housed under specific pathogen-free conditions with food and water provided ad libitum. All experiments were approved by the animal research ethics board of Dalhousie University.

Mast cell reconstitution

Bone marrow-derived mast cells (BMMCs) were generated from the bone marrow of WBB6F1-+/+ (+/+) mice according to the method of Tertian et al. (27), a minimum of 98% pure mast cells were used. W/Wv mice were locally reconstituted as previously described (28). Cells derived from +/+ mice (0.5 x 106) were locally injected into the right ear pinna of W/Wv mice and allowed to mature for 10 wk.

Histology

Carnoy’s fixed, paraffin-embedded ear pinna skin sections from W/Wv mice with and without prior local mast cell reconstitution were stained with Alcian blue and Safranin O. The numbers of granulated mast cells were counted in 10 randomly selected microscopic fields (at x 1000 magnification) per section.

Induction of local skin responses to bacterial products

Mice received an intradermal (i.d.) injection into the right ear pinna of 2.5 µg purified Staphylococcus aureus derived PGN (Fluka BioChemika distributed by Sigma-Aldrich) in 25 µl of saline and 25 µl of diluent in the left ear pinna. After 18 h mice were sacrificed, and their draining auricular LNs were excised. A LN-derived single cell suspension was prepared, counted, washed, and resuspended in RPMI 1640 medium. Either cytocentrifuge preparations were made or flow cytometric analysis of the LN-derived single cell suspension was performed as described below. For experiments using locally mast cell reconstituted W/Wv mice both ear pinnae were injected with PGN.

Induction of local skin reactions using IgE/Ag

Mice received an i.d. injection into the ear pinna of 70 µg of purified mouse anti-trinitrophenyl (TNP) IgE prepared from the B cell line TIB-141 (American Type Culture Collection) in 25 µl of PBS or diluent control (as stated). After a resting period, to allow excess IgE to dissipate (7–14 days), mice were challenged with an i.v. injection of 5 mg/ml TNP-BSA (Biosearch Technologies) in 250 µl of saline. Mice were sacrificed, and their draining auricular LN excised after 24 h.

Immunohistochemistry and cell counts

Cytocentrifuge preparations of LN cell suspensions were fixed, washed with PBS, and incubated with 3% BSA. Slides were then incubated with anti-Langerin Ab/CD207, clone 959F3, rat IgG1 (DCGM4) (0.75 µg/ml) (courtesy of Dr. S. Saeland, Schering-Plough, Levallois-Penet, France) or isotype-matched control Ab for 16–18 h at room temperature. Slides were washed and incubated with biotinylated goat anti-mouse Ab, then streptavidin-HRP (DAKO LSAB-2 System) and aminoethylcarbazole substrate (Zymed Laboratories) were used to detect Ab binding. At least 2000 cells were assessed/coded slide.

Flow cytometry

Cells were washed twice with 2% FBS/PBS, fixed with 1% paraformaldehyde/PBS for 30 min, and washed. The cells were permeabilized with 0.1% saponin/2% FBS/PBS and stained with anti-Langerin (CD207) Ab, or an isotype control and washed twice. Cells were incubated with the secondary Ab, an FITC-labeled mouse anti-rat IgG Ab for 20 min, followed by further washing. To block free Ab binding sites, the cells were incubated with 5% rat serum and 20 µg/ml hamster IgG. Cells were washed again and then stained for cell surface markers with a PE-conjugated anti-CD86, or isotype-matched control as well as an allophycocyanin-conjugated anti-CD11c or isotype-matched control. For analysis 3 x 104 cells were acquired with a FACSCalibur (BD Bioscience Pharmingen) and analyzed with CellQuest software (BD Bioscience Pharmingen). All Abs were purchased from BD Bioscience Pharmingen.

Examining the role of histamine receptors

To determine the role of histamine H1 and H2 receptors in the PGN-mediated response, PGN or control diluent were injected in to the ear pinnae 90 min after either H1 antagonist pyrilamine (50 mg/kg), the H2 antagonist cimetidine (50 mg/kg) (Sigma-Aldrich) or diluent (control) were injected i.p. Eighteen hours later mice were sacrificed and LNs were harvested and responses were evaluated as described above.

Mediators analysis

TNF, GM-CSF, IL-1beta, leukotriene C4 (LTC4), and CCL3 (MIP-1{alpha}) production was examined in cell-free supernatants harvested after 4h or 18h incubation of BMMCs with TNP-BSA or PGN in the presence of fresh or heat inactivated (56°C for 30 min) normal mouse plasma at 37°C. For TNP-BSA treatments, some groups of cells were previously sensitized by 24–48 h of incubation with monoclonal IgE anti-TNP. GM-CSF and CCL3 content of supernatants was measured via a commercial ELISA kit (R&D Systems). TNF and IL-1beta contents of supernatants was measured via an "in-house" ELISA as previously described (29) using the following Abs: polyclonal goat anti-mTNF (R&D Systems) for coating, anti-mouse TNF mAb biotin-labeled (Perbio Science) for detection, monoclonal rat IgG1anti-mouse IL-1beta for coating (R&D Systems), and anti-mouse IL-1beta Ab biotin-labeled for detection, respectively. LTC4 production was assessed 20 min following BMMC incubation with or without the above mentioned activators using an ELISA, as previously described by Volland et al. (30).

Degranulation and beta-hexsaminidase assay

BMMCs in HEPES-Tyrode’s buffer were incubated with the above-mentioned activators for 20 min at 37°C, both supernatants and pellets were analyzed for beta-hexsaminidase according to the method of Schwartz et al. (31).

Statistical methods

Following confirmation of appropriate data distribution, differences between left and right LNs were evaluated using a paired Student’s t test. Differences in responses between animal groups were compared using an unpaired Student’s t test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PGN-induced LN activation is mast cell-dependent

To determine the role of mast cells in PGN induced LN activation, mast cell deficient W/Wv mice and mast cell containing +/+ mice were injected with PGN into the right ear pinna and saline into the left ear pinna. After 18h, the draining auricular LNs were excised, and the total LN cellularity was determined. In mast cell containing +/+ mice a significant increase in the total number of cells was observed in the LN draining the PGN-injected site compared with LN draining the saline injected site. In contrast, no increase in the total number of cells was observed in the LN draining the PGN-injected site compared with saline injected sites in W/Wv mice (Fig. 1). In keeping with previous studies (22), the majority of the increase in total LN cellularity observed could be accounted for by changes in the numbers of CD3-positive T cells (data not shown).


Figure 1
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 1. PGN-induced LN hypertrophy is mast cell dependent. Genetically mast cell-deficient W/Wv mice, and their mast cell containing counterparts, +/+ mice, received a saline injection as a control in one ear pinna and PGN (100 ng/ml) injection in the contralateral ear pinna. W/Wv mice reconstituted with mast cells in one ear pinna only (W/Wv + MC) received PGN injection into both ear pinnae. After 18 h, the draining LNs were harvested, and total cells within the LNs were counted. All bars represent the mean value ± SEM (n = 5). * represents p < 0.05. Representative results of three similar independent experiments.

 
To determine whether mast cells are critical for inducing LN hypertrophy in response to PGN, mast cell deficient W/Wv mice were locally reconstituted by i.d. injection with BMMCs in the right ear only. After a 10-wk resting period, to allow mast cells to mature in vivo, mice were injected with PGN into both ear pinnae. After 18 h, the ear pinna draining auricular LNs were excised and the total cellularity was determined. A significant increase in the total number of cells was observed in the mast cell reconstituted site compared with nonreconstituted site confirming the requirement of mast cells to induce LN hypertrophy in response to PGN. Ear pinna skin was routinely harvested to confirm effective and consistent mast cell reconstitution. For example, in a representative experiment the mean numbers of cells with metachromatic granules (mast cells) were found to be 5.0 ± 0.4 cells per field (n = 5), while the equivalent mast cell numbers in unreconsituted control ears of W/Wv mice were 0.08 ± 0.1 cells per field (n = 5).

PGN-induced LN activation is not TNF dependent

To determine the role of TNF in PGN-induced LN hypertrophy, TNF-deficient mice and their wild-type controls were injected with PGN into the right ear pinna and saline into the left ear pinna. After 18 h, the cellularity of the draining auricular LN was determined. TNF-deficient and control mice had a similar increase in LN cellularity in response to PGN (Fig. 2a).


Figure 2
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 2. PGN-induced LN hypertrophy is TNF independent while IgE/Ag-induced LN activation requires TNF. a, TNF-deficient mice and controls received a saline injection as a control in one ear pinna and PGN injection in the contralateral ear. After 18 h, draining LN tissues were harvested, and total LN cells were counted. b, TNF-deficient mice and controls received a saline injection in one ear pinna and anti-TNP IgE injection in the contralateral ear pinna. After 14 days, mice were injected with TNP-BSA i.v., and 24 h later, the draining LN tissues were harvested and total cells were counted. All numbers represent the mean value ± SEM (n = 5). ** represents p < 0.01; *** represents p < 0.001.

 
To compare this response, with the role of TNF in LN responses following IgE-mediated mast cell activation, TNF-deficient mice and their wild type controls were injected with anti-TNP IgE into the right ear pinna and saline into the left ear pinna. After 7 days mice were challenged with TNP-BSA i.v. and after a further 24 h the draining auricular LNs were excised and the total LN cellularity was determined. In wild-type mice, a significant increase in the total number of cells was observed in the LN draining the IgE-injected site compared with LN draining the saline injected side. This highly mast cell-dependent response (26) was completely abrogated in TNF-deficient mice (Fig. 2b).

PGN-induced LC migration is mast cell dependent

The role of mast cells in LC migration out of the skin and into the draining LNs, in response to S. aureus derived PGN, was then determined. Mast cell deficient W/Wv mice and mast cell containing +/+ mice were injected with PGN into the right ear pinna and saline into the left ear pinna. After 18 h, the numbers of Langerin-positive (CD207) cells within the draining auricular LNs were determined. In mast cell containing +/+ mice, a significant increase in the total number of cells was observed in the LN draining the PGN-injected site compared with control side. In contrast, no increase in the number of Langerin-positive cells were observed in the LN draining the PGN-injected site compared with saline injected sites in mast cell-deficient W/Wv mice (Fig. 3). Following local mast cell reconstitution of W/Wv mice in one ear the LC migration response was restored (Fig. 3).


Figure 3
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 3. PGN induced LC migration is mast cell dependent. Genetically mast cell-deficient W/Wv mice, and their normal congenic +/+ mice received a saline injection as a control in one ear pinna and PGN injection in the contralateral ear pinna. W/Wv reconstituted with mast cells in one ear pinna only, with 10 wk allowed postreconstitution for mast cells to mature (W/Wv + MC) received PGN injection into both ear pinnae. After 18 h, draining LN tissues were harvested, and Langerin-positive DC were counted using anti-Langerin/CD207 immunohistochemistry. All numbers represent the mean value ± SEM (n = 8). * represents p < 0.05. Representative results of three similar independent experiments.

 
TNF dependence of LC migration

Using a similar experimental design, the TNF-dependence of the LC migration response was determined. TNF-deficient mice had a small but significant increase in the number of Langerin-positive cells in the LN draining the PGN-injected site compared with saline injected site (Fig. 4a). This response was only 31.5% of the response in TNF containing control animals, demonstrating an important role for TNF in this process.


Figure 4
View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 4. PGN induced LC migration is partially TNF independent while IgE/Ag induced LC migration is TNF dependent. a, TNF-deficient mice and their normal control mice received a saline injection as a control in one ear pinna and PGN injection in the contralateral ear. After 18 h, draining LN tissues were harvested, and Langerin-positive DC were counted. b, TNF-deficient mice and controls received a saline injection as a control in one ear pinna and anti-TNP IgE injection in the contralateral ear pinna. After 14 days, mice were injected with TNP-BSA i.v., and 24 h later, the draining LN tissues were harvested and Langerin-positive DC were counted using anti-Langerin/CD207 flow cytometry. All numbers represent the mean value ± SEM (n = 5/group). * represents p < 0.05; *** represents p < 0.001. # represents p < 0.01 when comparing PGN injected side of TNF-deficient mice compared with the PGN injected side in wild-type control mice after subtraction of the baseline numbers of cells observed in nodes from the saline-injected side of each mouse strain.

 
An IgE/Ag mediated system of local mast cell activation has previously been used to demonstrate the importance of mast cell activation in the induction of LC migration (26). Here, we also determined the role of TNF in LC migration following IgE-mediated mast cell activation. TNF deficient mice and their wild type controls were injected with anti-TNP IgE into the right ear pinna and saline into the left ear pinna. After 14 days, mice were challenged with TNP-BSA i.v. After 24 h, the draining auricular LNs were excised and the numbers of Langerin-positive cells were determined. In wild type mice a significant increase in the number of Langerin-positive cells was observed in the LN draining the IgE-injected site compared with LN draining the saline injected side. This IgE/Ag induced response was completely abrogated in TNF-deficient mice (Fig. 4b).

PGN-induced LN activation and migration is TLR2, TLR4, and MyD88 independent

PGN has previously been shown to activate immune effector cells through TLR2. The contributions of specific TLRs and the adapter molecule MyD88 were therefore examined. TLR2-deficient mice (3), MyD88-deficient mice (32) with the appropriate control mice (C57BL/6), TLR4-deficient C57BL10ScNJ mice, and their appropriate control C57BL/10J were injected with PGN into the right ear pinna and saline into the left ear pinna and draining LNs examined. The PGN-induced increases in total LN cellularity were not reduced in TLR2, TLR4, or MyD88-deficient animals when compared with control animals (Fig. 5a). TLR2, TLR4 and MyD88 deficient mice also all had significant increases in the number of Langerin-positive cells in the PGN-injected side compared with saline injected side, with the TLR2–/– mice having a significantly (p < 0.001) greater response to PGN then the C57BL/6 controls (Fig. 5b).


Figure 5
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 5. PGN-induced LN hypertrophy and LC migration is not TLR2, TLR4, or MyD88 dependent. C57BL/6, TLR2-deficient, MyD88-deficient, TLR4-deficient, and WT control mice received a saline injection as a control in one ear pinna and PGN injection in the contralateral ear pinna. After 18 h, draining LN tissues were harvested, and total cells and Langerin-positive DC cells were counted using anti-Langerin/CD207 flow cytometry. a, mean ± SEM numbers of total cells/draining LN. b, mean ± SEM number of Langerin/CD207-positive DC/draining LN (n = 5). * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001. Representative results of two similar independent experiments.

 
PGN-induced LC migration is complement component C3 dependent

To examine the contribution of complement activation we used C3-deficient mice. Lack of this early complement component renders mice unable to activate complement via the classical, alternate, or mannose binding pathways. Both C3-deficient mice and controls were treated with PGN in one ear pinna and evaluated as described above. Notably, the increase in draining LN total cellularity was significantly reduced following PGN injection in C3-deficient mice compared with control mice (Fig. 6a). Unlike their congenic controls, C3-deficient mice did not show a significant increase in the number of Langerin-positive cells in the LN draining the PGN injected ear pinna compared with the saline injected site (Fig. 6b).


Figure 6
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 6. PGN-induced LN activation and LC migration requires complement C3. C3-deficient mice and C57BL/6 mice received a saline injection in one ear pinna and PGN injection in the contralateral ear pinna. After 18 h, draining LN tissues were harvested, and total LN cells and Langerin-positive cells were counted. a) total cells/draining LN. b, Langerin/CD207-positive DC/draining LN. For IgE-mediated mast cell activation C3-deficient mice and controls received a saline injection as a control in one ear pinna and anti-TNP IgE injection in the contralateral ear pinna; 7 days later, mice were injected with TNP-BSA i.v. After 24 h, draining LN tissues were harvested, and Langerin-positive DC were counted. c, Total cells/draining LN. d, Langerin/CD207 positive DC/draining LN. All numbers represent the mean value ± SEM (n = 5). *, p < 0.05; **, p < 0.01; ***, p < 0.001.

 
To confirm that C3-deficient mice were capable of mounting a normal LN hypertrophy and LC response, these mice and controls were injected with anti-TNP IgE into the right ear pinna and saline into the left ear pinna. After 7 days, mice were challenged with TNP-BSA i.v. After an additional 24 h, the draining auricular LNs were excised. Both groups of mice had a significant increase in total cellularity of LN draining the IgE-injected side compared with LN draining the saline injected side (Fig. 6c), although this increase was attenuated in C3-deficient mice. The LC increases observed as a result of IgE-mediated mast cell activation were unchanged in C3-deficient mice compared with their controls (Fig. 6d).

Histamine receptors H1 and H2 do not have a major role in the response to PGN

LC migration in response to IgE-mediated mast cell activation has been previously shown to be histamine-dependent and was inhibited by >90% following treatment with the H2 receptor antagonist cimetidine (26). Therefore, C57BL/6 mice were pretreated with pyrilamine (H1 antagonist) 50 mg/kg, cimetidine (H2 antagonist) 50 mg/kg, or diluent control i.p 90 min before PGN and saline ear pinna injections. After 18 h, the draining auricular LNs were examined. Neither the increase in the total cellularity of LNs nor the migration of LC into the nodes was reduced by antihistamine receptors treatment (Fig. 7).


Figure 7
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 7. Blocking histamine receptor H1 or H2 does not inhibit LN activation or LC migration in response to PGN. C57BL/6 mice were injected with diluent, pyrilamine, or cimetidine i.p. 90 min before PGN and saline injection into the ear pinnae. After 18 h, LN tissue was harvested, and total cells and Langerin-positive DC cells were counted. a, mean ± SEM numbers of total cells/draining LN. b, mean ± SEM number of Langerin/CD207-positive DC/draining LN (n = 5). *, p < 0.05; **, p < 0.01; ***, p < 0.001. Representative results of two similar experiments.

 
The Langerin-positive cells observed in the skin draining LN have undergone maturation

To examine the maturational status of LC within auricular nodes following PGN treatment, LN cells were stained with the maturation marker CD86. The proportion of CD11c+ cells that were CD86+ remained high (>80%) in all experimental groups. TLR2, TLR4, MyD88, C3, and TNF-deficient mice all demonstrated similar proportions of CD86+/Langerin-positive cells within the nodes following saline or PGN treatment of the ear pinnae (Table I).


View this table:
[in this window]
[in a new window]
  		Table I. CD11c and CD86 positive cell populations in the draining auricular nodes of various mouse strains 18 h after PGN or saline or 24 h after IgE/Ag or saline injection of the ear pinnaa

 
Langerin-positive cell increases are associated with increases in CD11c+cells within the LNs

The proportion of CD11c+ LN DC that were Langerin-positive and the overall number of CD11c+ cells/node were also determined (Table I). C57BL/6 mice, TLR2, TLR4, and MyD88-deficient mice showed significant increases in the number of CD11c+ cells in the LN draining PGN-injected sites, with the TLR2–/– mice having a significantly (p < 0.05) greater response to PGN than the C57BL/6 mice. In contrast, C3-deficient mice showed significantly (p < 0.05) lower numbers of CD11c+ cells in the LN draining PGN-injected sites. C57BL/6 mice injected with diluent, pyrilamine, or cimetidine had similar responses to control C57BL/6 mice. TNF-deficient mice and their congenic controls both showed similar increases in the number of CD11c+ cells in LN draining PGN injection sites. The number of CD11c+ cells/node were also determined in response to IgE-mediated mast cell activation, C3-deficient mice showed a small but significant increase in the number of CD11c+ cells, while TNF-deficient mice showed no significant increase in the number of CD11c+ cells in the IgE-injected side compared with saline.

Comparison of key mediators produced by mast cells in response to PGN or IgE/Ag stimulation

In view of the marked differences in the apparent mechanism of mast cell dependent responses to IgE/Ag and PGN in vivo we examined the in vitro mediator production of murine BMMCs in response to these stimuli. PGN activation was examined in the presence of mouse plasma containing either active or heat-inactivated complement. Mast cell production of major regulators of DC maturation was examined by ELISA, under all activation conditions (Table II). IgE/Ag activation induced substantial degranulation above control sensitized cells (mean = 29.8 ± 6.5%) while PGN in either the presence or absence of active complement did not induce significant degranulation under these conditions (mean = 3.8 ± 5.1%). Similarly, IgE/Ag activated cells produced significantly more TNF (mean = 614.3 ± 86.8 pg/ml) than control cells (mean = 300.2 ± 99.5pg/ml) while PGN did not induce a TNF response. In marked contrast, PGN in the presence of complement containing plasma induced a significant GM-CSF response (p < 0.05) that was not observed following IgE/Ag activation of the same cell preparations. LTC4 production was observed in response to both PGN and IgE. However, by far the greatest LTC4 response was induced by IgE/Ag activation. PGN in the presence of complement induced significantly more LTC4 (p < 0.05) than when combined with heat-inactivated plasma. The role of complement in enhancing responses to PGN was further confirmed by measurement of the CCL3 response of BMMC to PGN in the presence of heat-inactivated or control mouse plasma. In the presence of active complement, mast cells produced a mean of 487.1 ± 223 pg/ml of this chemokine compared with a baseline level of 86.2 ± 30.8 pg/ml, while in the absence of active complement a mean of only 70.6 ± 31.3 pg/ml was observed (n = 3).


View this table:
[in this window]
[in a new window]
  		Table II. BMMC mediators, following IgE/Ag or PGN activation in the presence or absence of an active complement (C') cascadea

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The mast cell’s contribution to the development of acquired immune responses has not been fully elucidated. Previous studies have demonstrated important interactions with DCs and T cells as well as mast cell dependent induction of LN hypertrophy. Such studies have used models of IgE-mediated mast cell activation and Gram-negative bacterial infection, associated with substantial degranulation and TNF production by mast cells. PGN from Gram-positive bacteria such as S. aureus is also known to activate mast cells in vivo and in vitro (23, 33). However, it is not a potent inducer of human mast cell TNF production, and, in the absence of complement, has only moderate effects as a mast cell degranulating agent (34, 35). PGN can activate the immune system through multiple mechanisms including interaction with TLR2 (3, 36, 37), NOD family members (6, 7, 8, 9) and activation of the complement pathway (11, 12, 13).

In the current study, we examined the role of mast cells in the migration of LCs from the skin and into the draining LN as well as the development of LN hypertrophy following i.d. PGN administration. We compared responses to PGN with those observed following IgE/Ag mediated mast cell activation. Using the W/Wv mast cell-deficient mouse model and appropriate local mast cell reconstitutions we demonstrated that mast cells are essential for both LN hypertrophy and LC migration in response to PGN. Previous studies, using LPS administration to mast cell-deficient animals, have demonstrated that there is no fundamental defect in the ability of LCs to migrate or LN hypertrophy to occur in the W/Wv mouse (26). This observation is further supported by efficient responses to PGN following local mast cell reconstitution of W/Wv mice in one ear pinna. Injection of the contralateral mast cell-deficient ear pinna, in the same animals, with PGN yielded little or no response.

In view of previous reports (23) of TLR expression by mast cells and PGN activation of murine mast cells via TLR2, we initially considered the role of TLR-mediated signaling in these responses. Surprisingly, when PGN was administered to the skin of TLR2-deficient animals both LN hyperplasia and LC migration were observed. Indeed, there was a trend toward enhanced responses in TLR2-deficient animals when compared with matched controls. Similarly, when TLR4- or MyD88-deficient animals were used, both LC migration and LN hypertrophy responses to PGN remained intact. These data suggested that alternate TLRs using MyD88 were also not responsible for the observed mast cell dependent responses. However, we cannot rule out a potential contribution by TLRs signaling through alternate pathways or a role for NOD family members.

PGN is an excellent activator of complement working through the classical, alternate or mannose binding pathways. All of these pathways are ineffective in C3-deficient mice. Using such animals we demonstrated that both LC migration and LN hypertrophy in response to PGN are complement C3 dependent. Mast cells have receptors for a number of complement products including C3a and C5a. These observations raise the possibility that complement products might contribute to the activation of mast cells in the skin following PGN administration. Since C3 deficiency has been reported to be associated with a number of functional defects in other immune effector cells (38, 39) we examined responses to a complement independent, mast cell dependent stimulus in these mice. IgE/Ag mediated activation of mast cells in the skin yielded similar LC responses to those in control C3 containing mice. These results demonstrate that the mast cell’s ability to mobilize LCs is not inhibited in C3-deficient mice, thus confirming the role of complement in the mast cell dependent response to PGN. One potential model for this response would involve PGN activation of complement and subsequent activation of mast cells by complement split products (40) leading to the production of mediators, such as GM-CSF, with the ability to induce maturation and migration of resident LCs. However, since LCs also express complement receptors (41), complement products may also contribute to their maturation and migration directly.

The LN hypertrophy response to IgE/Ag mediated activation was reduced in C3 deficient animals when compared with control animals. This suggests that fundamental defects in this response, associated with C3 deficiency, could contribute to the observed lack of LN hypertrophy response to PGN.

Mast cells produce multiple mediators that may contribute to DC maturation and migration as well as LN hypertrophy responses (17, 18, 42, 43). These include GM-CSF, IL-1beta, TNF, LTC4, and histamine that can be produced following exposure to bacterial products (34, 44, 45). TNF and histamine have been implicated in multiple studies of mast cell dependent immune regulation. Histamine has been demonstrated to influence the maturation of DCs as well as the polarization of subsequent T cell responses (46, 47, 48). We have previously observed that the LC response, following IgE mediated mast cell activation, is highly histamine (H2) dependent while LN hypertrophy, in response to the same stimulus, was not. PGN induced LC migration and LN hypertrophy were both profoundly mast cell dependent; however, they were not significantly inhibited by either H1 or H2 receptor blockade. These observations do not rule out a role for histamine in modifying the functional characteristics of LCs or other DC populations in this model, but underline the existence of alternate mechanisms of mast cell mediated induction of LC migration to the draining LN.

TNF has been implicated as a critical cytokine in multiple mast cell-mediated models of immune modulation and acute inflammation (14, 15, 21, 22, 49, 50, 51, 52, 53). Mast cells have a unique ability to store and rapidly release TNF during degranulation; in addition, they can produce newly synthesized TNF in response to a variety of stimuli (19, 20, 54, 55, 56). TNF-deficient mice had a significantly reduced LC migration response, compared with wild type mice, following either IgE-mediated or PGN induced mast cell activation. However, the LC response to PGN was not entirely inhibited in the absence of TNF, suggesting important contributions by other mediators. The role of TNF in the migration of other DC subsets has not been examined in this model, however when CD11c+ DCs were evaluated as a whole, similar increases in these cells were observed following PGN activation in both TNF-containing and TNF-deficient mice suggesting that not all DC subsets are subject to the same TNF dependent events in response to PGN. Recent studies of a murine model of contact hypersensitivity to FITC have revealed that early recruitment of DCs into LNs draining the skin and airways is partially mast cell and TNF dependent (49), in keeping with the results of the current study.

TNF-deficient mice developed a similar level of LN hypertrophy as control mice following PGN administration. These results are in marked contrast to other models of mast cell dependent LN hypertrophy induced by IgE-mediated mast cell activation (Fig. 4) or Gram-negative bacterial infection which are highly TNF dependent (22). These data demonstrate the existence of at least two distinct mechanisms whereby mast cells can contribute to the development of LN hypertrophy. A number of mast cell mediators, including Leukotrienes, IL-6, IL-1beta, and GM-CSF, might contribute to this process. Multiple mechanisms have been described whereby LN hypertrophy can occur including increased migration of T cells into the LN as a result of remodeling and other events enhancing T cell recruitment (22) and decreased emigration of T cells out of the LN. Mast cells could contribute to these processes through local mediator production and subsequent lymphatic transport of mediators or activated cells to the draining node.

Mast cell modulation of the maturation of LCs as well as the development of LN hypertrophy has important implications for the development of acquired immune responses. Bryce et al. have demonstrated a role for mast cells and IgE in promoting the development of contact hypersensitivity responses (57) in keeping with recent findings of Suto et al. (49). However, this is not a consistent finding in all models of contact hypersensitivity (58, 59). The role of mast cells is likely to be highly dependent on the conditions used to induce responses and the nature and extent of mast cell mediator production that is initiated. PGN induced LC migration and maturation may be of particular importance in the context of atopic dermatitis where >90% of patients have been demonstrated to be infected with S. aureus. PGN-activated mast cells could potentially modify the process of immune sensitization to multiple environmental Ags by enhancing the proportion of mature LC’s migrating to the draining LNs. Mast cells may impact on the polarization and effectiveness of T cell responses either through well described effects of their mediators on DCs (48, 60) or through more direct mast cell T cell interactions that have been recently described (21, 61).

Overall, this study demonstrates that PGN induced LC migration and LN hypertrophy are highly mast cell and complement (C3) dependent, although independent of TLR2 or MyD88. The ability of TNF-deficient animals to undergo LN hypertrophy in response to PGN indicates a novel TNF-independent mechanism whereby mast cells can contribute to this process, quite distinct from the mechanism(s) involved in response to IgE/Ag or Gram-negative bacterial infection. Modulation of these pathways should provide novel opportunities to intervene in the earliest states of development of acquired immune responses to pathogens or environmental Ags.


   Acknowledgments
 
We thank Dr. Ian Haidl for critical reading of the manuscript, Eric Albert, Yi-song Wei, and Pat Colp for their excellent technical assistance, Dr. S. Akira (Osaka University) for providing the TLR2- and MyD88-deficient animals, and Dr. S. Saeland for his provision of anti-CD207 Abs necessary for this study.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Canadian Institutes for Health Research. D.M.J. was supported by a scholarship from the Cultural Bureau of Saudi Arabia. Back

2 Address correspondence and reprint requests to Dr. Jean S. Marshall, Department of Pathology, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia B3H 1X5, Canada. E-mail address: Jean.Marshall{at}Dal.ca Back

3 Abbreviations used in this paper: PGN, peptidoglycan; NOD, nucleotide-binding oligomerization domain; LC, Langerhans cell; LN, lymph node; DC, dendritic cell; BMMC, bone marrow-derived mast cell; i.d., intradermal; TNP, trinitrophenyl; LTC4, leukotriene C4. Back

Received for publication November 28, 2005. Accepted for publication May 2, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Schleifer, K. H., O. Kandler. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36: 407-477. [Free Full Text]
  2. Stewart-Tull, D. E.. 1980. The immunological activities of bacterial peptidoglycans. Annu. Rev. Microbiol. 34: 311-340. [Medline]
  3. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451. [Medline]
  4. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274: 17406-17409. [Abstract/Free Full Text]
  5. Yoshimura, A., E. Lien, R.R. Ingalls, E. Tuomanen, R. Dziarski, D. Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5. [Abstract/Free Full Text]
  6. Girardin, S. E., L.H. Travassos, M. Herve, D. Blanot, I.G. Boneca, D.J. Philpott, P.J. Sansonetti, D. Mengin-Lecreulx. 2003. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 278: 41702-41708. [Abstract/Free Full Text]
  7. Chamaillard, M., M. Hashimoto, Y. Horie, J. Masumoto, S. Qiu, L. Saab, Y. Ogura, A. Kawasaki, K. Fukase, S. Kusumoto, et al 2003. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4: 702-707. [Medline]
  8. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, et al 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease. J. Biol. Chem. 278: 5509-5512. [Abstract/Free Full Text]
  9. Girardin, S. E., I. G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D. J. Philpott, P. J. Sansonetti. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872. [Abstract/Free Full Text]
  10. Dziarski, R.. 2004. Peptidoglycan recognition proteins (PGRPs). Mol. Immunol. 40: 877-886. [Medline]
  11. Greenblatt, J., R. J. Boackle, J. H. Schwab. 1978. Activation of the alternate complement pathway by peptidoglycan from streptococcal cell wall. Infect. Immun. 19: 296-303. [Abstract/Free Full Text]
  12. Ma, Y. G., M. Y. Cho, M. Zhao, J. W. Park, M. Matsushita, T. Fujita, B. L. Lee. 2004. Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J. Biol. Chem. 279: 25307-25312. [Abstract/Free Full Text]
  13. Verbrugh, H. A., W. C. Van Dijk, R. Peters, M. E. Van Der Tol, J. Verhoef. 1979. The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. Immunology 37: 615-621. [Medline]
  14. Echtenacher, B., D. N. Mannel, L. Hultner. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381: 75-77. [Medline]
  15. Malaviya, R., T. Ikeda, E. Ross, S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-{alpha}. Nature 381: 77-80. [Medline]
  16. Marshall, J. S., D. M. Jawdat. 2004. Mast cells in innate immunity. J. Allergy Clin. Immunol. 114: 21-27. [Medline]
  17. Plaut, M., J. H. Pierce, C. J. Watson, J. Hanley-Hyde, R. P. Nordan, W. E. Paul. 1989. Mast cell lines produce lymphokines in response to cross-linkage of Fc{epsilon}RI or to calcium ionophores. Nature 339: 64-67. [Medline]
  18. Burd, P. R., H. W. Rogers, J. R. Gordon, C. A. Martin, S. Jayaraman, S. D. Wilson, A. M. Dvorak, S. J. Galli, M. E. Dorf. 1989. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J. Exp. Med. 170: 245-257. [Abstract/Free Full Text]
  19. Gordon, J. R., S. J. Galli. 1990. Mast cells as a source of both preformed and immunologically inducible TNF-{alpha}/cachectin. Nature 346: 274-276. [Medline]
  20. Gordon, J. R., S. J. Galli. 1991. Release of both preformed and newly synthesized tumor necrosis factor {alpha} (TNF-{alpha})/cachectin by mouse mast cells stimulated via the Fc{epsilon}RI: a mechanism for the sustained action of mast cell-derived TNF-{alpha} during IgE-dependent biological responses. J. Exp. Med. 174: 103-107. [Abstract/Free Full Text]
  21. Nakae, S., H. Suto, M. Kakurai, J. D. Sedgwick, M. Tsai, S. J. Galli. 2005. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc. Natl. Acad. Sci. USA 102: 6467-6472. [Abstract/Free Full Text]
  22. McLachlan, J. B., J. P. Hart, S. V. Pizzo, C. P. Shelburne, H. F. Staats, M. D. Gunn, S. N. Abraham. 2003. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol. 4: 1199-1205. [Medline]
  23. Supajatura, V., H. Ushio, A. Nakao, S. Akira, K. Okumura, C. Ra, H. Ogawa. 2002. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest. 109: 1351-1359. [Medline]
  24. Galli, S. J., S. Nakae, M. Tsai. 2005. Mast cells in the development of adaptive immune responses. Nat. Immunol. 6: 135-142. [Medline]
  25. Stoitzner, P., S. Holzmann, A. D. McLellan, L. Ivarsson, H. Stossel, M. Kapp, U. Kammerer, P. Douillard, E. Kampgen, F. Koch, et al 2003. Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J. Invest. Dermatol. 120: 266-274. [Medline]
  26. Jawdat, D. M., E. J. Albert, G. Rowden, I. D. Haidl, J. S. Marshall. 2004. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J. Immunol. 173: 5275-5282. [Abstract/Free Full Text]
  27. Tertian, G., Y. P. Yung, D. Guy-Grand, M. A. Moore. 1981. Long-term in vitro culture of murine mast cells. I. Description of a growth factor-dependent culture technique. J. Immunol. 127: 788-794. [Abstract]
  28. Nakano, T., T. Sonoda, C. Hayashi, A. Yamatodani, Y. Kanayama, T. Yamamura, H. Asai, T. Yonezawa, Y. Kitamura, S. J. Galli. 1985. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice: evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J. Exp. Med. 162: 1025-1043. [Abstract/Free Full Text]
  29. McCurdy, J. D., T. J. Lin, J. S. Marshall. 2001. Toll-like receptor 4-mediated activation of murine mast cells. J. Leukocyte Biol. 70: 977-984. [Abstract/Free Full Text]
  30. Volland, H., B. Vulliez Le Normand, S. Mamas, J. Grassi, C. Creminon, E. Ezan, P. Pradelles. 1994. Enzyme immunometric assay for leukotriene C4. J. Immunol. Methods 175: 97-105. [Medline]
  31. Schwartz, L. B., K. F. Austen, S. I. Wasserman. 1979. Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J. Immunol. 123: 1445-1450. [Abstract/Free Full Text]
  32. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150. [Medline]
  33. Supajatura, V., H. Ushio, A. Nakao, K. Okumura, C. Ra, H. Ogawa. 2001. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J. Immunol. 167: 2250-2256. [Abstract/Free Full Text]
  34. McCurdy, J. D., T. J. Olynych, L. H. Maher, J. S. Marshall. 2003. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170: 1625-1629. [Abstract/Free Full Text]
  35. Arock, M., E. Ross, R. Lai-Kuen, G. Averlant, Z. Gao, S. N. Abraham. 1998. Phagocytic and tumor necrosis factor {alpha} response of human mast cells following exposure to Gram-negative and Gram-positive bacteria. Infect. Immun. 66: 6030-6034. [Abstract/Free Full Text]
  36. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274: 17406-17409. [Abstract/Free Full Text]
  37. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, D. Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5. [Abstract/Free Full Text]
  38. Barrington, R., M. Zhang, M. Fischer, M. C. Carroll. 2001. The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180: 5-15. [Medline]
  39. Carroll, M. C.. 2000. The role of complement in B cell activation and tolerance. Adv. Immunol. 74: 61-88. [Medline]
  40. Nilsson, G., M. Johnell, C. H. Hammer, H. L. Tiffany, K. Nilsson, D. D. Metcalfe, A. Siegbahn, P. M. Murphy. 1996. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157: 1693-1698. [Abstract]
  41. Morelli, A., A. Larregina, I. Chuluyan, E. Kolkowski, L. Fainboim. 1996. Expression and modulation of C5a receptor (CD88) on skin dendritic cells: chemotactic effect of C5a on skin migratory dendritic cells. Immunology 89: 126-134. [Medline]
  42. Gordon, J. R., P. R. Burd, S. J. Galli. 1990. Mast cells as a source of multifunctional cytokines. Immunol. Today 11: 458-454. [Medline]
  43. Williams, C. M., J. W. Coleman. 1995. Induced expression of mRNA for IL-5. IL-6, TNF-{alpha}, MIP-2 and IFN-{gamma} in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology 86: 244-249. [Medline]
  44. Malaviya, R., S. N. Abraham. 2000. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J. Leukocyte Biol. 67: 841-846. [Abstract]
  45. Lin, T. J., R. Garduno, R. T. Boudreau, A. C. Issekutz. 2002. Pseudomonas aeruginosa activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 {alpha} and beta. J. Immunol. 169: 4522-4530. [Abstract/Free Full Text]
  46. Caron, G., Y. Delneste, E. Roelandts, C. Duez, N. Herbault, G. Magistrelli, J. Y. Bonnefoy, J. Pestel, P. Jeannin. 2001. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol. 166: 6000-6006. [Abstract/Free Full Text]
  47. Caron, G., Y. Delneste, E. Roelandts, C. Duez, J. Y. Bonnefoy, J. Pestel, P. Jeannin. 2001. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J. Immunol. 167: 3682-3686. [Abstract/Free Full Text]
  48. Mazzoni, A., H. A. Young, J. H. Spitzer, A. Visintin, D. M. Segal. 2001. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 108: 1865-1873. [Medline]
  49. Suto, H., S. Nakae, M. Kakurai, J. D. Sedgwick, M. Tsai, S. J. Galli. 2006. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 176: 4102-4112. [Abstract/Free Full Text]
  50. Wang, Y., H. Thorlacius. 2005. Mast cell-derived tumour necrosis factor-{alpha} mediates macrophage inflammatory protein-2-induced recruitment of neutrophils in mice. Br. J. Pharmacol. 145: 1062-1068. [Medline]
  51. Biedermann, T., M. Kneilling, R. Mailhammer, K. Maier, C. A. Sander, G. Kollias, S. L. Kunkel, L. Hultner, M. Rocken. 2000. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192: 1441-1452. [Abstract/Free Full Text]
  52. Watanabe, N., B. Akikusa, S. Y. Park, H. Ohno, L. Fossati, G. Vecchietti, J. E. Gessner, R. E. Schmidt, J. S. Verbeek, B. Ryffel, et al 1999. Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fc{gamma} receptors. Blood 94: 3855-3863. [Abstract/Free Full Text]
  53. Wershil, B. K., Z. S. Wang, J. R. Gordon, S. J. Galli. 1991. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent: partial inhibition of the reaction with antiserum against tumor necrosis factor-{alpha}. J. Clin. Invest. 87: 446-453. [Medline]
  54. Varadaradjalou, S., F. Feger, N. Thieblemont, N. B. Hamouda, J. M. Pleau, M. Dy, M. Arock. 2003. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 33: 899-906. [Medline]
  55. Stassen, M., C. Muller, C. Richter, C. Neudorfl, L. Hultner, S. Bhakdi, I. Walev, E. Schmitt. 2003. The streptococcal exotoxin streptolysin O activates mast cells to produce tumor necrosis factor {alpha} by p38 mitogen-activated protein kinase- and protein kinase C-dependent pathways. Infect. Immun. 71: 6171-6177. [Abstract/Free Full Text]
  56. Dreskin, S. C., S. N. Abraham. 1999. Production of TNF-{alpha} by murine bone marrow derived mast cells activated by the bacterial fimbrial protein, FimH. Clin. Immunol. 90: 420-424. [Medline]
  57. Bryce, P. J., M. L. Miller, I. Miyajima, M. Tsai, S. J. Galli, H. C. Oettgen. 2004. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20: 381-392. [Medline]
  58. Mekori, Y. A., S. J. Galli. 1985. Undiminished immunologic tolerance to contact sensitivity in mast cell-deficient W/Wv and Sl/Sld mice. J. Immunol. 135: 879-885. [Abstract]
  59. Geba, G. P., W. Ptak, G. M. Anderson, V. Paliwal, R. E. Ratzlaff, J. Levin, P. W. Askenase. 1996. Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J. Immunol. 157: 557-565. [Abstract]
  60. Skokos, D., H. G. Botros, C. Demeure, J. Morin, R. Peronet, G. Birkenmeier, S. Boudaly, S. Mecheri. 2003. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J. Immunol. 170: 3037-3045. [Abstract/Free Full Text]
  61. Galli, S. J., J. Kalesnikoff, M. A. Grimbaldeston, A. M. Piliponsky, C.M. Williams, M. Tsai. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23: 749-786. [Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. Gounaris, N. R. Blatner, K. Dennis, F. Magnusson, M. F. Gurish, T. B. Strom, P. Beckhove, F. Gounari, and K. Khazaie
T-Regulatory Cells Shift from a Protective Anti-Inflammatory to a Cancer-Promoting Proinflammatory Phenotype in Polyposis
Cancer Res., July 1, 2009; 69(13): 5490 - 5497.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. J. Swindle, J. W. Coleman, F. R. DeLeo, and D. D. Metcalfe
Fc{epsilon}RI- and Fc{gamma} Receptor-Mediated Production of Reactive Oxygen Species by Mast Cells Is Lipoxygenase- and Cyclooxygenase-Dependent and NADPH Oxidase-Independent
J. Immunol., November 15, 2007; 179(10): 7059 - 7071.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. L. Christy and M. A. Brown
The Multitasking Mast Cell: Positive and Negative Roles in the Progression of Autoimmunity
J. Immunol., September 1, 2007; 179(5): 2673 - 2679.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Burke, L. M. Ganley-Leal, A. Khatri, and L. M. Wetzler
Neisseria meningitidis PorB, a TLR2 Ligand, Induces an Antigen-Specific Eosinophil Recall Response: Potential Adjuvant for Helminth Vaccines?
J. Immunol., September 1, 2007; 179(5): 3222 - 3230.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B.-S. Feng, S.-H. He, P.-Y. Zheng, L. Wu, and P.-C. Yang
Mast Cells Play a Crucial Role in Staphylococcus aureus Peptidoglycan-Induced Diarrhea
Am. J. Pathol., August 1, 2007; 171(2): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Heib, M. Becker, T. Warger, G. Rechtsteiner, C. Tertilt, M. Klein, T. Bopp, C. Taube, H. Schild, E. Schmitt, et al.
Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice
Blood, August 1, 2007; 110(3): 946 - 953.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jawdat, D. M.
Right arrow Articles by Marshall, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jawdat, D. M.
Right arrow Articles by Marshall, J. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS